| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Regulation FD Disclosure
Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer |
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition
Third quarter net revenues of $193 million an increase of 16% year-over-year, driven by 19% growth in active patients worldwide |
| 01 Oct 2026 |
8-K: Regulation FD Disclosure
Baar, Switzerland – October 1, 2026 – Novocure (Nasdaq: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable locally advance... |
| 09 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
(b) Timothy Scannell, a current director of NovoCure Limited (the “Company”), has retired from the Board and his seat was formally vacated pursuant to the Company’s Articles of Association effective September 2, 2026. Mr. Scannell's reti... |
| 01 Sep 2026 |
8-K: Other Events
In mid-August 2026, NovoCure Limited (the "Company," "we," or "us") through a subsidiary, became aware of unauthorized access to some of its information systems. Upon detecting the unauthorized access, the Company activated its cybersecu... |
| 23 Jul 2026 |
8-K: Results of Operations and Financial Condition
Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications |
| 30 Jun 2026 |
8-K: Regulation FD Disclosure
The CE Mark is supported by results from the Phase 3 PANOVA-3 trial demonstrating a statistically significant improvement in overall survival (OS) for patients treated with Optune Pax concomitant with gemcitabine and nab-paclitaxel |
| 18 Jun 2026 |
8-K: Regulation FD Disclosure
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma |
| 05 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The purpose of this NovoCure Limited Amended and Restated 2024 Omnibus Incentive Plan is to enhance the profitability and value of the Company for the benefit of its shareholders by enabling the Company to offer Eligible Employees, Consu... |
| 30 Apr 2026 |
8-K: Results of Operations and Financial Condition
Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio® |
| 09 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On behalf of Novocure GmbH, we would like to thank you for your willingness to assume the role of Chief Medical Officer while concurrently performing your responsibilities as Chief Innovation Officer. Your readiness to take on this expan... |
| 26 Mar 2026 |
8-K: Regulation FD Disclosure
Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update |
| 24 Feb 2026 |
8-K: Regulation FD Disclosure
On February 2, 2026, the registrant's U.S. subsidiary, Novocure Inc. (the "Company") received a letter dated January 29, 2026 from the Centers for Medicare & Medicaid Services ("CMS") that the Company's billing privileges for its product... |
| 11 Feb 2026 |
8-K: Regulation FD Disclosure
Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer |
| 05 Feb 2026 |
8-K: Regulation FD Disclosure
On January 30, 2026, the registrant's U.S. subsidiary, Novocure Inc. (the "Company") received a letter dated January 29, 2026 from the Centers for Medicare & Medicaid Services ("CMS") that the Company's billing privileges for its product... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition
Preliminary full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million |
| 01 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
THIS SEPARATION AND RELEASE AGREEMENT (“Agreement”) made November 24, 2025 (the “Effective Date”), between Novocure GmbH (including its successors and assigns, the “Company”), and Ashley Cordova (the “Executive”). |
| 30 Oct 2025 |
8-K: Results of Operations and Financial Condition
Quarterly net revenues of $167 million, up 8% year-over-year, with 4,416 active patients on therapy as of September 30, 2025 |
| 15 Sep 2025 |
8-K: Regulation FD Disclosure
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC) |
Loading...